Discontinued Product1-Naphthoxylactic acid (Cat. No. 0849) has been withdrawn from sale for commercial reasons.
Metabolite of propranolol.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Shiga et al (1993) Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects. J.Clin.Pharmacol. 33 756 PMID: 8408738
Shiga et al (1993) The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects. Eur.J.Clin.Pharmacol. 44 489 PMID: 8359189
Bourne (1981) The metabolism of β-adrenoceptor blocking drugs. Prog.Drug Metabolism. Eds. Bridges, J. W. & Ch 6 77
Keywords: 1-Naphthoxylactic acid, 1-Naphthoxylactic acid supplier, Non-selective, Adrenergic, Beta, Receptors, 0849, Tocris Bioscience
Citations for 1-Naphthoxylactic acid
Citations are publications that use Tocris products.
Currently there are no citations for 1-Naphthoxylactic acid.
Reviews for 1-Naphthoxylactic acid
There are currently no reviews for this product. Be the first to review 1-Naphthoxylactic acid and earn rewards!
Have you used 1-Naphthoxylactic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.